Market: NASD |
Currency: USD
Address: 3940 Trust Way
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
📈 Benitec Biopharma Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$25.71
-
Upside/Downside from Analyst Target:
99.96%
-
Broker Call:
15
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.058824 |
- |
2023-07-26 |
- |
Stock split |
|
Total Amount for 2023: $0.058824 |
| 2020 |
- |
$0.666667 |
- |
2020-04-15 |
- |
Stock split |
|
Total Amount for 2020: $0.666667 |
| 2019 |
- |
$0.100000 |
- |
2019-11-18 |
- |
Stock split |
|
Total Amount for 2019: $0.100000 |
| 2018 |
- |
$0.765000 |
- |
2018-06-01 |
- |
Dividend payout |
|
Total Amount for 2018: $0.765000 |
| 2015 |
- |
$0.250000 |
- |
2015-06-16 |
- |
Stock split |
|
Total Amount for 2015: $0.250000 |
📅 Earnings & EPS History for Benitec Biopharma Inc.
| Date | Reported EPS |
|---|
| 2025-08-07 | - |
| 2025-05-14 | -0.24 |
| 2025-02-14 | -0.33 |
| 2024-11-14 | -0.48 |
| 2024-05-13 | -1.64 |
| 2024-02-13 | -2.64 |
| 2023-11-13 | -2.76 |
| 2023-05-15 | -2.72 |
| 2023-02-13 | -3.4 |
| 2022-11-10 | -7.99 |
| 2022-09-02 | -10.54 |
| 2022-05-16 | -6.8 |
| 2021-02-09 | -12.92 |
| 2020-11-13 | -41.65 |
| 2020-10-06 | -46.58 |
| 2020-08-14 | -33.32 |
📰 Related News & Research
No related articles found for "benitec biopharma".
